



Xipere® (triamcinolone acetonide) – New drug approval

- On October 25, 2021, [Bausch + Lomb and Clearside Biomedical](#) announced the [FDA approval](#) of [Xipere \(triamcinolone acetonide\)](#), for the treatment of macular edema associated with uveitis.
- Xipere is an injection formulation of triamcinolone that is administered in the suprachoroidal space.
- The efficacy of Xipere was established in a 6-month, randomized, double-masked, sham-controlled study in patients with macular edema associated with anterior-, intermediate-, posterior-, or pan-uveitis. Patients were treated at baseline and week 12. The primary endpoint was the proportion of patients in whom best corrected visual acuity (BCVA) had improved by ≥ 15 letters from baseline after 24 weeks of follow-up.
 - Overall, 47% and 16% of patients met the primary endpoint in the Xipere and control groups, respectively (treatment difference 31%, 95% CI: 15, 46; $p < 0.01$).
- Xipere is contraindicated in patients with ocular or periocular infections and in patients with known hypersensitivity to triamcinolone acetonide or any other components of this product.
- Warnings and precautions for Xipere include potential corticosteroid-related effects and alterations in endocrine function.
- The most common adverse reactions ($\geq 10\%$ and at a rate greater than control) with Xipere use were elevated intraocular pressure and eye pain.
- The recommended dose of Xipere is 4 mg (0.1 mL of the 40 mg/mL injectable suspension) administered via suprachoroidal injection.
- Bausch + Lomb and Clearside plan to launch Xipere in the first quarter of 2022. Xipere will be available as a 40 mg/mL suspension in a single-dose glass vial.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.